Navigation Links
Neuralstem chief scientific officer to take part in World Stem Cell Summit plenary session

Neuralstem, Inc. (NYSE Amex: CUR) announced that the Chairman of its Board of Directors and Chief Scientific Officer, Dr. Karl Johe, PhD, will take part in a plenary discussion entitled, Current and Future Clinical Trials and Stem Cell Therapies, at the World Stem Cell Summit on October 5, in Detroit, MI ( Dr. Johe is the creator of Neuralstems neural stem cell technology.

The panel will be moderated by Dr. Eva Feldman, PhD, MD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, and includes as well Dr. Jonathan Glass, MD, Professor of Neurology & Director Emory ALS Center Emory University, and Dr. Nicholas Boulis, MD, Assistant Professor Neurosurgery Emory University.

Neuralstem is currently sponsoring a Phase I trial of its spinal cord stem cells in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrigs disease) at the ALS Center at Emory University, in Atlanta, GA. Dr. Feldman is the Principal Investigator, Dr. Glass is the Site Principal Investigator and Dr. Boulis is the Co-Investigator and Neurosurgeon.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in a Phase I safety clinical trial for Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. In addition to ALS, the company is targeting major central nervous system diseases, including traumatic spinal cord injury, ischemic spastic paraplegia, and Huntington's disease. The company has also submitted an IND application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Through its proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company plans to initiate clinical trials to treat Alzheimer's disease and major depression with its lead compound, as well as pursue additional indications, including traumatic brain injury, posttraumatic stress syndrome, stroke and schizophrenia.


Contact: Deanne Eagle
Neuralstem, Inc.

Related medicine news :

1. Neuralstem stem cells survive and differentiate into neurons in rats with stroke
2. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
3. Neuralstem updates clinical trial progress
4. National Institute of General Medical Sciences chief wins prestigious public service award
5. FDA Chief Says More Egg Recalls Possible
6. Spectrum Surgical Instruments Appoints President, Chief Operating Officer
7. DKI Direct Appoints Greg Lewis as Chief Marketing Officer
8. BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role
9. Steri -7 Appoints BioNeutral Group Inc. Chief Scientist Dr. Andy Kielbania for Expanded Role
10. Former NIH Chief Joins Children's National Medical Center
11. Martek Biosciences Chief Scientific Officer, Dr. Norman Salem, 2010 Recipient of Alex Leaf Distinguished Scientist Award
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a ... customers 10% off of their purchase of lice treatment product. In addition, customers will ... to a company spokesperson. “Finding lice is a sure way to ruin the holidays, ...
(Date:11/27/2015)... LOS ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only ... age of 30 (see Table 1-1 ). More than 3.7 billion people under ... simplex virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
(Date:11/27/2015)... ... ... CBD College is proud to announce that on November 20th, ... its Diagnostic Medical Sonography program. CBD College is honored to join this very short ... universities in the state of California make the cut. CBD College is officially the ...
(Date:11/27/2015)... ... 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his ... is one of Joplin's most famous and beautiful concert posters. The concert was held ... Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's stardom ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
Breaking Medicine Technology: